Whether you’re newly diagnosed or wanting to explore new treatments, SRF Carebox Connect provides the resources you need to find trials that could be the right fit for you. SRF...
Read More
Last week, the CONQUEST team headed to Argentina to connect with local physicians! CONQUEST is a global platform clinical trial created by the Scleroderma Research Foundation to accelerate the development...
Read More
Boehringer Ingelheim has announced that its Phase III FIBRONEER-ILD trial examining nerandomilast met its primary endpoint, measuring lung function through forced vital capacity (FVC) at 52 weeks. While nerandomilast remains...
Read More
Rare Disease Day is coming soon—a time to shine a light on the millions of people living with rare diseases, like scleroderma. At the Scleroderma Research Foundation (SRF), we believe...
Read More
CONQUEST is proud to be a sponsor of the EUSTAR Course 2025, which took place from February 6-8 in Bordeaux, France. Dr. Gregory Gordon, Chief Medical Officer of the Scleroderma...
Read More
Turning hope into action begins with a strategic approach to funding scleroderma research. When it comes to our core research portfolio, our Scientific Advisory Board, made up of some of...
Read More
Navigating clinical trials can feel overwhelming, but finding accurate, reliable information shouldn’t be. Our new clinical trial page is designed to empower you with resources and support to make informed...
Read More
Since 1987, this dedicated community has stood shoulder to shoulder with the SRF, helping to drive research toward a cure for scleroderma. Because of your generosity and commitment, 2024 was...
Read More
We are excited to share that CONQUEST, a global platform clinical trial created by the Scleroderma Research Foundation, has opened 68 sites in 13 countries. Individuals with interstitial lung disease...
Read More
Navigating clinical trials can feel overwhelming, but finding accurate, reliable information shouldn’t be. Our new clinical trial page is designed to empower you with resources and support to make informed...
Read More
